Dr. Joel Raichlen, M.D

NPI: 1588842835
Total Payments
$250,109
2021 Payments
$18,360
Companies
3
Transactions
27

Payment Breakdown by Category

Consulting$250,004 (100.0%)
Food & Beverage$104.74 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $250,004 21 100.0%
Food and Beverage $104.74 6 0.0%

Top Paying Companies

Company Total Records Latest Year
AstraZeneca Pharmaceuticals LP $249,390 20 $0 (2021)
Ipsen Innovation $614.25 1 $0 (2020)
CSL Behring $104.74 6 $0 (2017)

Payment History by Year

Year Amount Transactions Top Company
2021 $18,360 5 AstraZeneca Pharmaceuticals LP ($18,360)
2020 $53,654 3 AstraZeneca Pharmaceuticals LP ($53,040)
2019 $177,990 13 AstraZeneca Pharmaceuticals LP ($177,990)
2017 $104.74 6 CSL Behring ($104.74)

All Payment Transactions

27 individual payment records from CMS Open Payments — Page 1 of 2

Date Company Product Nature Form Amount Type
09/14/2021 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $3,060.00 General
Category: Cardiovascular and Metabolism
07/18/2021 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $4,080.00 General
Category: Cardiovascular and Metabolism
06/30/2021 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $5,100.00 General
Category: Cardiovascular and Metabolism
06/25/2021 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $5,610.00 General
Category: Cardiovascular and Metabolism
06/24/2021 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $510.00 General
Category: Cardiovascular and Metabolism
04/20/2020 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $6,120.00 General
Category: Cardiovascular and Metabolism
03/24/2020 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $46,920.00 General
Category: Cardiovascular and Metabolism
03/17/2020 Ipsen Innovation Consulting Fee Cash or cash equivalent $614.25 General
11/17/2019 AstraZeneca Pharmaceuticals LP Consulting Fee Cash or cash equivalent $2,550.00 General
11/11/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $28,560.00 General
Category: Cardiovascular and Metabolism
10/20/2019 AstraZeneca Pharmaceuticals LP Consulting Fee Cash or cash equivalent $2,040.00 General
10/15/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $22,950.00 General
Category: Cardiovascular and Metabolism
09/15/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $14,280.00 General
Category: Cardiovascular and Metabolism
08/17/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $9,690.00 General
Category: Cardiovascular and Metabolism
07/15/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $7,140.00 General
Category: Cardiovascular and Metabolism
06/18/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $13,260.00 General
Category: Cardiovascular and Metabolism
05/29/2019 AstraZeneca Pharmaceuticals LP Consulting Fee Cash or cash equivalent $20,910.00 General
05/20/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $7,650.00 General
Category: Cardiovascular and Metabolism
04/22/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $29,580.00 General
Category: Cardiovascular and Metabolism
03/24/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $12,240.00 General
Category: Cardiovascular and Metabolism
03/04/2019 AstraZeneca Pharmaceuticals LP CRESTOR (Drug) Consulting Fee Cash or cash equivalent $7,140.00 General
Category: Cardiovascular and Metabolism
12/12/2017 CSL Behring Food and Beverage In-kind items and services $22.86 General
12/12/2017 CSL Behring Food and Beverage In-kind items and services $17.36 General
12/12/2017 CSL Behring Food and Beverage In-kind items and services $12.17 General
12/12/2017 CSL Behring Food and Beverage In-kind items and services $5.48 General

About Dr. Joel Raichlen, M.D

Dr. Joel Raichlen, M.D is a Cardiovascular Disease healthcare provider based in Bryn Mawr, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/07/2008. The National Provider Identifier (NPI) number assigned to this provider is 1588842835.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joel Raichlen, M.D has received a total of $250,109 in payments from pharmaceutical and medical device companies, with $18,360 received in 2021. These payments were reported across 27 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($250,004).

Practice Information

  • Specialty Cardiovascular Disease
  • Location Bryn Mawr, PA
  • Active Since 02/07/2008
  • Last Updated 02/07/2008
  • Taxonomy Code 207RC0000X
  • Entity Type Individual
  • Practice Solo Practitioner
  • NPI Number 1588842835

Products in Payments

  • CRESTOR (Drug) $223,890

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Cardiovascular Disease Doctors in Bryn Mawr